BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Julphar
Boehringer Ingelheim
Fuji
US Department of Justice
US Army
Novartis
Federal Trade Commission
QuintilesIMS
Argus Health

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,445,003

« Back to Dashboard

Which drugs does patent 8,445,003 protect, and when does it expire?

Patent 8,445,003 protects VASCEPA and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.
Summary for Patent: 8,445,003
Title:Stable pharmaceutical composition and methods of using same
Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular related diseases.
Inventor(s): Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/458,496
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,445,003

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Subscribe
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,445,003

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,551,521 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,663,662 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,298,554 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,617,594 Stable pharmaceutical composition and methods of using same ➤ Subscribe
9,060,983 Stable pharmaceutical composition and methods of using same ➤ Subscribe
9,060,982 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,703,185 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,709,475 Stable pharmaceutical composition and methods of using same ➤ Subscribe
9,072,715 Stable pharmaceutical composition and methods of using same ➤ Subscribe
8,445,013 Stable pharmaceutical composition and methods of using same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,445,003

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2011011538 ➤ Subscribe
Malaysia 157120 ➤ Subscribe
New Zealand 595852 ➤ Subscribe
South Korea 20120000109 ➤ Subscribe
South Korea 101343249 ➤ Subscribe
Lithuania 2424356 ➤ Subscribe
New Zealand 627238 ➤ Subscribe
Russian Federation 2011148362 ➤ Subscribe
Russian Federation 2538691 ➤ Subscribe
Russian Federation 2014131716 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Julphar
Argus Health
Merck
AstraZeneca
Fish and Richardson
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot